Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Call Transcript

James Gruber: Sure. Historically, Eton has not provided full year guidance in advance. However, with ongoing M&A activity, if there was a transformational transaction in the second half of 2023, we would likely provide some guidance on how that would impact the portfolio going forward.

David Krempa: And the last question we have is, what are your commercial expectations for ET-400? And I’ll let Sean answer that one.

Sean Brynjelsen: Thanks. So ET-400 really was a patient and doctor request. It’s a product that is desperately needed by especially young patients two and below. Sometimes they have trouble with the granularity of the sprinkles, and so they’re forced to go to compounding pharmacies to obtain a liquid suspension of hydrocortisone that is not approved for, say, there’s no demonstration of safety and efficacy. Also Pfizer had a liquid version many years ago that had issues and they got pulled from the market. Our product, our hydrocortisone oral solution is room temperature-stable. We expect a 24-month expiration date. And it’s a product that we think is really going to drive sales of the franchise. We think there are approximately 10,000 patients, 18 and under, that can benefit from ALKINDI or ET-400. And I feel confident that we’ll hit several thousand of those patients with the combination of these two products.

David Krempa: That concludes our questions. Thank you, everyone, for joining us today.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.